本文已被:浏览 19次 下载 2次
Received:August 12, 2025 Published Online:May 22, 2026
Received:August 12, 2025 Published Online:May 22, 2026
中文摘要: 目的 评价布比卡因脂质体髂筋膜间隙阻滞(FICB)应用于老年衰弱手术患者的安全性和有效性,及对患者术后疼痛和谵妄的影响。方法 前瞻性选取2023年10月至2025年6月于如皋市人民医院行全髋关节置换术的患者60例,采用随机数字表法分为两组(每组30例),两组均实施腰硬联合麻醉(CSEA),在CSEA前,研究组采用超声引导下布比卡因脂质体 133 mg 行 FICB,对照组采用超声引导下 0.25%布比卡因 30 mL 行 FICB。两组均于神经阻滞操作后开始泵注右美托咪定0.8 μg /kg,持续10 min后,改为0.4 μg·kg-1·h-1维持至手术结束前10 min。记录并比较以下指标:术前1 d及术后3 d 的简易精神状态检查量表(MMSE)评分及肿瘤坏死因子-α(TNF-α)水平,术后24 h和48 h静息时、运动时的视觉模拟评分法(VAS)评分,镇痛泵按压次数,补救镇痛情况,谵妄等不良反应发生率,及术后首次下床活动时间。结果 术后3 d,两组患者MMSE评分均较术前1 d降低,且研究组高于对照组(P<0.05);术后3 d,两组患者TNF-α浓度均较术前升高,且研究组低于对照组(P<0.05)。与对照组比较,研究组术后 24 h、48 h 静息时、运动时 VAS 评分显著降低(P<0.05),研究组术后镇痛泵按压次数(1.87±0.43 vs 8.63±1.71,t=20.998,P<0.05)和补救镇痛率(6.67% vs 30.00%,χ2=5.450,P<0.05)低于对照组。研究组谵妄发生率(6.67%)略低于对照组(20.00%),但差异无统计学意义(P=0.255)。研究组术后恶心呕吐发生率显著低于对照组(P<0.05),两组患者术后头晕发生率及术后首次下床行走时间比较差异无统计学意义(P>0.05)。结论 在CSEA前采用布比卡因脂质体行FICB联合右美托咪定,虽未显著降低谵妄发生率,但在缓解术后疼痛、减少炎症反应及不良反应方面更具优势,安全性高,适用于老年患者衰弱全髋关节置换术。
Abstract:Objective To evaluate the safety and efficacy of fascia iliaca compartment block(FICB)with liposomal bupivacaine in elderly frail surgical patients,and to investigate its influence of postoperative pain and delirium on patients. Methods Sixty patients undergoing total hip arthroplasty at Rugao People's Hospital from October 2023 to June 2025 were prospectively enrolled and randomly divided into two groups(n=30 per group). Both groups underwent combined spinal-epidural anesthesia (CSEA). Before CSEA,the study group received ultrasound-guided FICB with 133 mg liposomal bupivacaine,while the control group received ultrasound-guided FICB with 30 mL of 0.25% bupivacaine.In both groups,dexmedetomidine was infused at 0.8 μg/kg for 10 min after nerve block,followed by continuous infusion at 0.4 μg·kg- 1·h- 1 until 10 min before the end of surgery. The following indicators were recorded and compared:Mini-Mental State Examination(MMSE)scores and tumor necrosis factor-α(TNF-α)level at preoperative day 1 and postoperative day 3;Visual Analogue Scale(VAS)scores at rest and during movement at 24 h and 48 h postoperatively;the number of analgesic pump compressions;the rate of rescue analgesia;the incidence of adverse reactions including delirium;and the time to first postoperative ambulation. Results On postoperative day 3,MMSE scores in both groups were lower than those on preoperative day 1,and the score in the study group was higher than that in the control group(P<0.05). On postoperative day 3,TNF-α levels in both groups were higher than those before surgery,and the level in the study group was lower than that in the control group(P<0.05). Compared with the control group,the study group had significantly lower VAS scores at rest and during movement at 24 h and 48 h postoperatively(P<0.05),fewer analgesic pump compressions(1.87±0.43 vs 8.63±1.71,t=20.998,P<0.05)and a lower rate of rescue analgesia(6.67% vs 30.00%,χ2=5.450,P<0.05). The incidence of delirium in the study group(6.67%)was slightly lower than that in the control group(20.00%),but the difference was not statistically significant(P=0.255). The incidence of postoperative nausea and vomiting in the study group was significantly lower than that in the control group(P<0.05). There was no significant difference in the incidence of postoperative dizziness or time to first postoperative ambulation between the two groups(P>0.05). Conclusion Using bupivacaine liposome for FICB before CSEA,combined with dexmedetomidine,although it does not significantly reduce the incidence of delirium,it has more advantages in relieving postoperative pain,reducing inflammatory response and adverse reactions,and has high safety,which is suitable for elderly frail patients undergoing total hip arthroplasty.
keywords: Liposomal bupivacaine Dexmedetomidine Frailty Fascia iliaca compartment block Combined spinal-epidural anesthesia Postoperative pain Delirium
文章编号: 中图分类号:R614 文献标志码:A
基金项目:国家自然科学基金(82301444);南通科技计划(指导性)项目(MSZ2023163);江苏卫生健康职业学院校级科研项目(JKC2022055);江苏省医学会医学科研面上项目[SYH-32021-0132(2025009)];江苏省老年健康科研立项项目(LKZ2025022)
引用文本:
